List of Actonel drug patents

Actonel is owned by Apil.

Actonel contains Risedronate Sodium.

Actonel has a total of 4 drug patents out of which 0 drug patents have expired.

Actonel was authorised for market use on 27 March, 1998.

Actonel is available in tablet;oral dosage forms.

Actonel can be used as treatment of osteoporosis in postmenopausal women, prevention and treatment of osteoporosis.

The generics of Actonel are possible to be released after 06 November, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7192938 APIL Method of treatment using bisphosphonic acid
May, 2023

(3 months from now)

US7718634 APIL Method of treatment using bisphosphonic acid
May, 2023

(3 months from now)

US7192938

(Pediatric)

APIL Method of treatment using bisphosphonic acid
Nov, 2023

(9 months from now)

US7718634

(Pediatric)

APIL Method of treatment using bisphosphonic acid
Nov, 2023

(9 months from now)

Drugs and Companies using RISEDRONATE SODIUM ingredient

Market Authorisation Date: 27 March, 1998

Treatment: Prevention and treatment of osteoporosis; Treatment of osteoporosis in postmenopausal women

Dosage: TABLET;ORAL

How can I launch a generic of ACTONEL before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in